Eupraxia Pharmaceuticals Inc. (TSX: EPRX)

Canada flag Canada · Delayed Price · Currency is CAD
4.630
0.00 (0.00%)
Jan 20, 2025, 10:39 AM EST
-12.14%
Market Cap 164.93M
Revenue (ttm) n/a
Net Income (ttm) -38.12M
Shares Out 35.62M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 800
Average Volume 10,027
Open 4.630
Previous Close 4.630
Day's Range 4.620 - 4.630
52-Week Range 3.070 - 7.640
Beta 1.57
RSI 59.12
Earnings Date Mar 21, 2025

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign struc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 29
Stock Exchange Toronto Stock Exchange
Ticker Symbol EPRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.